ctDNA monitoring detects response before scans

This is really a claim about moving cancer monitoring from the scan room to the blood draw. Northstar Response is built to measure tiny changes in circulating tumor DNA while a patient is on therapy, so an oncologist can see whether tumor burden is falling or rising between imaging visits, rather than waiting for a CT or MRI to show a visible size change. That matters because treatment decisions in advanced cancer are often made cycle by cycle, and earlier signal can mean switching ineffective therapy sooner.1 2 5 6

• Northstar Response is a tissue free ctDNA assay for treatment monitoring, not just a one time mutation finding test. BillionToOne says it uses methylation and single molecule counting to track more informative loci than older SNV based approaches, which is why it positions the product for serial blood based response checks during therapy.2 5 6
• The closest comparables show the same workflow logic. Natera Signatera and Guardant response monitoring products also aim to detect molecular response before scans, but they differ in setup. Signatera is tumor informed and needs tissue from the patient’s tumor to build a custom assay, while BillionToOne and Guardant emphasize tissue free monitoring from blood alone.3 4 6 7
• This product also changes the business mix. Prenatal testing is BillionToOne’s base, but oncology monitoring pushes it into a much larger market that includes therapy selection, response monitoring, and surveillance, where it competes with established liquid biopsy companies like Natera, Guardant Health, and Myriad.1 2

The next step is turning earlier molecular response into standard oncology workflow. If blood based monitoring keeps showing that it predicts progression weeks or months before imaging, these assays can become a routine checkpoint after each treatment cycle, which would make oncology a much larger and more recurring testing business for BillionToOne than prenatal alone.2 5 6 7